All News

I’ve learned that “survivor’s guilt” can be another symptom of our disease.

From Colin McFarlane and John Homme opening up about their cancer diagnoses to Pope Francis visiting a pediatric oncology ward, here’s what’s happening in the cancer space this week.

Columvi is the first bispecific antibody that can be administered to patients with relapsed or refractory diffuse large B-cell lymphoma for a defined period of time.

Watch Dr. Jerry Spivak, from Johns Hopkins University School of Medicine, discuss what is on the horizon in the management of polycythemia vera during the CURE® Educated Patient® MPN Summit.

Most patients with nonmetastatic castration-resistant prostate cancer were able to stay on their therapies long-term, research showed.

Mindfulness meditation can make a big difference in the treatment experience of patients.

I remember hearing somewhere that there’s no such thing as achieving the perfect balance; rather, life itself is an act of constant rebalancing. I've found that to be true in life with cancer.

Findings from a phase 3 trial demonstrated that half of patients with FLT3-ITD-mutant acute myeloid leukemia and detectable minimal residual risk derived a relapse-free survival benefit with Xospata.

Watch Dr. Nikolai Podoltsev, from Yale School of Medicine, discuss the current management of polycythemia vera during the CURE® Educated Patient® MPN Summit.

Patients with GIST have more treatment options than ever, with others currently under development.

Genetic testing is the norm for cancer patients with familial history. How did I let it slip through the crack?

Treatments for advanced endometrial cancer have progressed and improved with the use of immunotherapy with chemotherapy.

Watch Dr. Lucia Masarova, Dr. Laura C. Michaelis and Celia Militz answer questions about essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

The application for capivasertib plus Faslodex in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer has also been granted priority review, meaning that the FDA has six months to make a decision.

For patients who don’t speak English, there can be additional obstacles during their cancer journey. Resources, family, care providers, fellow patients and the law are on their side.

When starting chemotherapy, I was expecting hair and weight loss, but was caught off guard when my mouth began to hurt.

CAR-T cell therapies have not always been easy to access for patients with myeloma, though that is slowly changing, an expert explained.

Watch Dr. Laura C. Michaelis, from the Medical College of Wisconsin, discuss the current and future management of essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Patients with inactive early-stage chronic lymphocytic leukemia may benefit from a wait-and-watch approach compared with immediate treatment with Imbruvica, findings from a phase 3 trial showed.

A survey of cancer centers found that the majority of large centers are facing cisplatin and carboplatin shortages, and some are changing or delaying treatment because of it.

Sure, knowledge is power, but there’s comfort in naïveté, too, when it comes to expectations for cancer care.

Jakafi led to improved symptom score and spleen volume reductions in patients with myelofibrosis, regardless of anemia or transfusion status, recent research showed.

Watch Dr. Lucia Masarova, from MD Anderson Cancer Center, discuss risk stratifying patients with essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Because MPNs can cause chronic disease that spans years or even decades, some patients need their significant other to become their caregiver.

Maintenance Darzalex, with or without Pomalyst was safe and efficacious in treating patients with relapsed myeloma who underwent salvage autologous hematopoietic stem cell transplant.

Iclusig plus reduced-intensity chemotherapy led to improved outcomes for patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia, and should be the new standard of care, one expert said.

An ongoing trial is examining Calquence in older or frail patients with chronic lymphocytic leukemia — a group that is typically left out of clinical trials.

Patients and their caregivers may benefit from community support and education following an MPN diagnosis